NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes

About this update from Neogenomics, Inc.

[{"type":"text","content":"FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the \"Company\"), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced the pricing of concurrent underwritten public offerings of (a) 4,081,632 shares of its common stock at a public offering price of $49.00 per share (the \"common stock offering\") for gross proceeds to NeoGenomics from the common stock offering of $200.0 million, before deducting the underwriting discounts and commissions and estimated common stock offering expenses payable by NeoGenomics and (b) $300,000,000 aggregate principal amount of its 0.25% convertible senior notes due 2028 (the \"notes\") (the \"notes offering\"; collectively with the common stock offering, the \"offerings\") for gross proceeds to NeoGenomics from the notes offering of $300.0 million, before deducting the underwriting discounts and commissions and estimated notes offering expenses payable by NeoGenomics. In addition, NeoGenomics has granted the underwriters of the offerings a 30-day option to purchase up to an additional (a) 612,244 shares of its common stock at the public offering price, less underwriting discounts and commissions, and (b) $45,000,000 aggregate principal amount of the notes, less underwriting discounts and commissions and solely to cover over-allotments with respect to the notes offering. The size of the notes offering was increased from the previously announced amount. The offerings of the shares and the notes are expected to close on or about January 11, 2021, subject to the satisfaction of customary closing conditions.The notes will be senior, unsecured obligations of NeoGenomics, and will bear interest at a rate of 0.25% per year. Interest will be payable semi-annually and in arrears on January 15 and July 15 of each year, beginning on July 15, 2021. The notes will mature on January 15, 2028, unless earlier converted or repurchased.The notes may be converted at an initial conversion rate of 15.1172 shares of NeoGenomics' common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $66.15 per share and represents a conversion premium of approximately 35.0% to the public offering price of NeoGenomics' common stock in the common stock offering). Prior to the...

More updates from Neogenomics, Inc.